Small Molecule Inhibitors of ERG and ETV1 in Prostate Cancer
Abstract
The research involves laboratory studies utilizing xenograft models to test the hypothesis that targeting a member of the ETS transcription factor family with small molecules such as YK-4-279 may effectively treat prostate cancer. In year three, Dr. Morrissey was to evaluate the anti-tumor effect of the S-enantiomer of YK-4-279 on 4 human prostate xenograft lines subcutaneously and 2 lines intra-tibial. Dr. Uren supplied Dr. Morrissey with the required compound. The S-enantiomer of YK-4-279 had no significant effect on tumor growth on the first and second ERG+ xenograft. It had an effect on the third ERG+ xenograft line, and no effect on the control xenograft line. A gene expression analysis of the first study suggested a change in the expression of epithelial-mesenchymal transition associated genes in ERG treated tumors. However, immunohistochemical analyses of these proteins in the tumors of treated and untreated animals suggested the change in expression only occurred in a subset of cells within the tumors. Dr. Uren has met with and Skyped with Dr. Morrissey to ensure continued collaboration. We are currently completing a study on the effect of the S-enantiomer of YK-4-279 on intra-tibial tumors and have requested a no cost extension to complete the intra-tibial animal studies.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2015
- Accession Number
- AD1002720
Entities
People
- Colm Morrissey
Organizations
- University of Washington